India, April 22 -- Aktis Oncology Inc. (AKTS), a clinical-stage oncology company, is scheduled to present clinical imaging and dosimetry data for AKY-2519, a miniprotein radioconjugate targeting solid tumors in metastatic prostate cancer, at the 2026 annual meeting of the American Society of Clinical Oncology (ASCO) on May 30, 2026.
AKY-2519 is a novel, miniprotein radioconjugate targeting B7-H3 in solid tumors, including those in prostate and lung cancers. It contains the Actinium-225 (225Ac) alpha-emitting radioisotope that targets specific expressing tumors, facilitating anti-tumor activity by increasing penetration, internalization, and retention in cancer cells.
The data to be presented will include the normal tissue biodistribution ...